BDX vs BIO: Which Stock Is the Better Buy?
Becton, Dickinson and Company and Bio-Rad Laboratories, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BDX vs BIO, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Becton, Dickinson and Company (BDX) | Bio-Rad Laboratories, Inc. (BIO) | |
|---|---|---|
| Market cap | — | $7.8B |
| Revenue (latest FY) | $21.84B | $2.58B |
| Net income (latest FY) | $1.68B | $759.90M |
| Revenue growth (5y CAGR) | 6.3% | 0.3% |
| Net margin | 7.7% | 29.4% |
| Return on equity | 6.6% | 10.2% |
| P/E ratio | 28.9 | 48.8 |
| Dividend yield | 2.5% | — |
| Profitable years (of last 10) | 10 | 7 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BDX vs BIO breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BDX's full financials → Open BIO's full financials →More comparisons
Frequently asked questions
Which is bigger, BDX or BIO?
Market capitalization data is not available for both companies.
Which grows faster, BDX or BIO?
Over the last five fiscal years, Becton, Dickinson and Company grew revenue faster — 6.3%/yr versus 0.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.